CA2657670C - Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation - Google Patents

Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation Download PDF

Info

Publication number
CA2657670C
CA2657670C CA2657670A CA2657670A CA2657670C CA 2657670 C CA2657670 C CA 2657670C CA 2657670 A CA2657670 A CA 2657670A CA 2657670 A CA2657670 A CA 2657670A CA 2657670 C CA2657670 C CA 2657670C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
chloro
pyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2657670A
Other languages
English (en)
French (fr)
Other versions
CA2657670A1 (en
Inventor
Trevor T. Charvat
Cheng Hu
Jeff Jin
Yandong Li
Anita Melikian
Andrew M.K. Pennell
Sreenivas Punna
Solomon Ungashe
Yibin Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CA2657670A1 publication Critical patent/CA2657670A1/en
Application granted granted Critical
Publication of CA2657670C publication Critical patent/CA2657670C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2657670A 2006-07-14 2007-07-10 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation Active CA2657670C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83104206P 2006-07-14 2006-07-14
US60/831,042 2006-07-14
US94585407P 2007-06-22 2007-06-22
US60/945,854 2007-06-22
PCT/US2007/015786 WO2008008375A2 (en) 2006-07-14 2007-07-10 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation

Publications (2)

Publication Number Publication Date
CA2657670A1 CA2657670A1 (en) 2008-01-17
CA2657670C true CA2657670C (en) 2012-04-17

Family

ID=38670575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2657670A Active CA2657670C (en) 2006-07-14 2007-07-10 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation

Country Status (10)

Country Link
US (2) US7683176B2 (enExample)
EP (1) EP2049515B1 (enExample)
JP (1) JP5320291B2 (enExample)
CN (1) CN101511800B (enExample)
AT (1) ATE496905T1 (enExample)
AU (1) AU2007272972B2 (enExample)
CA (1) CA2657670C (enExample)
DE (1) DE602007012261D1 (enExample)
ES (2) ES2360741T3 (enExample)
WO (1) WO2008008375A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566387A1 (en) * 2004-05-12 2005-12-01 Chemocentryx, Inc. Aryl sulfonamides as chemokine receptor ccr9 antagonists
ATE496905T1 (de) * 2006-07-14 2011-02-15 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US7718683B2 (en) * 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
CA2720613A1 (en) * 2008-04-09 2009-10-15 Boehringer Ingelheim International Gmbh 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10
JP2013532688A (ja) 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG10201801794WA (en) 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
JP6321042B2 (ja) 2013-02-06 2018-05-09 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なハロゲン置換された化合物
CA2919552C (en) * 2013-07-29 2022-03-15 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
EA029826B1 (ru) * 2013-12-02 2018-05-31 Кемосентрикс, Инк. Соединения против ccr6
US20170002011A1 (en) 2013-12-23 2017-01-05 Norgine B.V. Benzene sulfonamides as ccr9 inhibitors
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
EP3922246A1 (en) * 2014-03-21 2021-12-15 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
IL292655B2 (en) 2014-10-06 2024-03-01 Chemocentryx Inc Ccr9 chemokine receptor inhibitor for use in a method of treating or reducing the development of inflammatory bowel disease
CN104341389A (zh) * 2014-10-19 2015-02-11 湖南华腾制药有限公司 一种三唑哌啶盐酸盐的制备方法
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
US10000458B2 (en) * 2016-03-31 2018-06-19 Sumitomo Chemical Company, Limited Production method of 1, 2, 4-triazole compound
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
CN109475537A (zh) * 2016-06-03 2019-03-15 坎莫森特里克斯公司 治疗肝纤维化的方法
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018157856A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
GB201705263D0 (en) 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
RU2020107152A (ru) 2017-07-18 2021-08-27 Байер Кропсайенс Акциенгезельшафт Замещенные 3-гетероарилокси-1н-пиразолы и их соли, а также применение в качестве гербицидных активных веществ
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
TWI904146B (zh) 2020-03-31 2025-11-11 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
CN115477626B (zh) * 2021-06-16 2024-08-02 上海璃道医药科技有限公司 N-取代苯基磺酰胺类化合物及其用途
CN118206536A (zh) * 2022-12-15 2024-06-18 上海璃道医药科技有限公司 N-取代苯基磺酰胺类化合物的固体形式

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612247A1 (de) 1991-11-15 1994-08-31 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von sulfonylverbindungen
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US6790540B2 (en) 2000-06-01 2004-09-14 Nippon Steel Chemical Co., Ltd. Organic electroluminescent element material and organic electroluminescent element
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US20060111351A1 (en) 2002-11-18 2006-05-25 Solomon Ungashe Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
JP4322062B2 (ja) * 2003-07-23 2009-08-26 日本発條株式会社 エンジンブロックおよびその製造方法
JP5090730B2 (ja) 2004-03-03 2012-12-05 株式会社きもと 光制御フィルムおよびそれを用いたバックライト装置
CA2566387A1 (en) 2004-05-12 2005-12-01 Chemocentryx, Inc. Aryl sulfonamides as chemokine receptor ccr9 antagonists
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2006076644A2 (en) 2005-01-14 2006-07-20 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007014008A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
ATE496905T1 (de) 2006-07-14 2011-02-15 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US7718683B2 (en) 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
AU2007275873B2 (en) 2006-07-14 2012-06-14 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides

Also Published As

Publication number Publication date
ES2358618T3 (es) 2011-05-12
AU2007272972A1 (en) 2008-01-17
US7683176B2 (en) 2010-03-23
CN101511800A (zh) 2009-08-19
WO2008008375A3 (en) 2008-03-06
ES2360741T3 (es) 2011-06-08
HK1131134A1 (en) 2010-01-15
DE602007012261D1 (de) 2011-03-10
US20080039504A1 (en) 2008-02-14
ATE496905T1 (de) 2011-02-15
AU2007272972B2 (en) 2011-12-01
US20100152186A1 (en) 2010-06-17
JP5320291B2 (ja) 2013-10-23
EP2049515B1 (en) 2011-01-26
US8445518B2 (en) 2013-05-21
JP2010504280A (ja) 2010-02-12
CN101511800B (zh) 2013-02-27
CA2657670A1 (en) 2008-01-17
EP2049515A2 (en) 2009-04-22
WO2008008375A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
AU2007272972B2 (en) Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis
AU2007275873B2 (en) Triazolyl phenyl benzenesulfonamides
US7718683B2 (en) Triazolyl phenyl benzenesulfonamides
US8198309B2 (en) N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides
US20100234364A1 (en) Ccr2 inhibitors and methods of use thereof
HK1131134B (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
HK1135091B (zh) 三唑基苯基苯磺酰胺

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251009